RecruitingNCT07502664

Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

Sponsor

Ray Therapeutics, Inc.

Enrollment

25 participants

Start Date

Feb 19, 2026

Study Type

OBSERVATIONAL

Conditions

Retinitis Pigmentosa Stargardt Macular Dystrophy Stargardt Disease Geographic Atrophy from Age-related Macular Degeneration X-linked Retinoschisis Retinal Dystrophies

Summary

The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment. The VRAI facilitates the development and refinement of existing endpoints specifically for testing patients with Low Vision.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with geographic atrophy from age-related macular degeneration, retinal dystrophies, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.